Safety Information
| Description | Publish Date | LINKS |
|---|---|---|
| Important safety information on Abacavir: Hypersensitivity reaction - educational slide deck | 15/02/2024 |  |
| Important safety information on Dolutegravir in Cameroon |
10/06/2018 |
|
| Important safety information on Non-steroidal anti-inflammatory drugs (NSAlDs) in Cameroon | 11/06/2021 | |
| Important safety information on Cephalosporins in Cameroon (Safety Notification_Cephalosporins and risk of seizure) | 01/03/2023 | |
Important safety information on Cephalosporins in Cameroon (Safety Notification_Cephalosporins and risk of neurotoxicity) |
07/03/2023 |
|
Important safety information on Amoxicillin / Amoxicillin and clavulanic acid containing products in Cameroon |
09/09/2023 | |
| Important safety information on Paroxetine in Cameroon (Safety Notification_EMA communication issued relating to Paroxetine label update) | 27-10-2023 | |
| Important safety information on Cefuroxime sodium in Cameroon (Safety Notification_Cefuroxime Class 4 Defect MHRA) | 30-10-2023 | |
| Important safety information on Topical Corticosteroids containing products in Cameroon | 15-11-2023 | |
Important safety information on Paroxetine containing products - Modifications of the information of medicines authorized by national procedure that contain Paroxetine |
21/01/2024 |
|
Important safety information on Acyclovir containing products - Safety Notification EMA-PRAC: The MAH has been requested to provide cumulative reviews of the below-mentioned issues in the next PBRER to be submitted for acyclovir |
02/01/2024 |
|
Important safety information on Acyclovir containing products - ACYCLOVIR/VALACYCLOVIR – RISK OF DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS) |
17/04/2024 |
|
